Gefitinib Intermediate CAS 199327-61-2 Purity >99.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of 7-Methoxy-6-(3-Morpholin-4-ylpropoxy)quinazolin-4(3H)-One (CAS: 199327-61-2) with high quality, intermediate of Gefitinib (CAS: 184475-35-2). Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Gefitinib Intermediates, Please contact: alvin@ruifuchem.com
| Chemical Name | 7-Methoxy-6-(3-Morpholin-4-ylpropoxy)quinazolin-4(3H)-One |
| Synonyms | 7-Methoxy-6-(3-Morpholinopropoxy)quinazolin-4(3H)-One; 7-Methoxy-6-[3-(4-Morpholinyl)propoxy]-4(3H)-Quinazolinone; 7-Methoxy-6-(3-Morpholinopropoxy)quinazolin-4-One |
| impurity | Gefitinib impurity 5; Gefitinib EP Impurity A |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 199327-61-2 |
| Molecular Formula | C16H21N3O4 |
| Molecular Weight | 319.36 g/mol |
| Melting Point | 242.0~247.0℃ |
| Density | 1.32±0.10 g/cm3 |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Items | Inspection Standards | Results |
| Appearance | White to Off-White Powder | Complies |
| Melting Point | 242.0~247.0℃ | 243.6~244.5℃ |
| Loss on Drying | <0.50% | 0.15% |
| Residue on Ignition | <0.20% | 0.11% |
| Single Impurity | <0.50% | <0.30% |
| Total Impurities | <1.00% | 0.30% |
| Purity / Analysis Method | >99.0% (HPLC) | 99.7% |
| 1H NMR Spectrum | Consistent with Structure | Complies |
| Conclusion | The product has been tested and complies with the given specifications | |
| Application | Intermediate of Gefitinib (CAS: 184475-35-2) | |
Package: Fluorinated Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃) and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
7-Methoxy-6-(3-Morpholin-4-ylpropoxy)quinazolin-4(3H)-One (CAS: 199327-61-2) is an intermediate / impurity of Gefitinib (CAS: 184475-35-2). Gefitinib is a highly specific anti-tumor targeted therapeutic drug developed by AstraZeneca, UK. Gefitinib is the first molecular targeted drug for the treatment of non-small cell lung cancer. It works by selectively inhibiting the signal transduction pathway of epidermal growth factor receptor tyrosine kinase (EGFR-TK). In August 2002, Gefitinib was first marketed in Japan as a first-line treatment for non-small cell lung cancer under the trade name Iressa. In May 2003, the U.S. Food and Drug Administration approved Gefitinib as the third-line monotherapy for patients with advanced non-small cell lung cancer who were ineffective with platinum-based anticancer drugs and docetaxel chemotherapy. At present, Gefitinib has been approved by Australia, Japan, Argentina, Singapore and South Korea for the treatment of advanced non-small cell lung cancer. On February 28, 2005, the China Food and Drug Administration approved Gefitinib for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that had previously received chemotherapy. It is not currently approved for use as first-line therapy for advanced NSCLC. On July 1, 2009, the European Medicines Agency officially approved Gefitinib for the first-line, second-line and third-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR gene mutations in adults.
